Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Peter

Showing results (91-100 of 505) with videos related to

Pageof 51
Sort By:
Acta Haematologica|September 17, 2015
Is Having Clonal Cytogenetic Abnormalities the Same as Having LeukaemiaMirko Farina, Giuseppe Rossi, Daniella Bellotti, et al.
Journal of Cancer Research and Clinical Oncology|April 18, 2016
Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemiaQian Jiang, Zheng-Chen Liu, Song-Xin Zhang, et al.
Acta Haematologica|July 6, 2026
Progression-free survival effect sizes in randomized controlled trials of targeted cancer therapies with positive outcomesWei Zhang, Wen Yan, Mengyun Chen, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 17, 2018
Tracking Kinematic and Kinetic Measures of Sit to Stand using an Instrumented Spine OrthosisRobert Peter Matthew, Sarah Seko, Jeannie Bailey, et al.
Journal of Sports Sciences|December 18, 2014
Lifesource XL-18 pedometer for measuring steps under controlled and free-living conditionsSam Liu, Dina Brooks, Scott Thomas, et al.
Endocrinology|August 18, 2016
Loss-of-Function Mutations in the Human Luteinizing Hormone Receptor Predominantly Cause Intracellular RetentionClaire Louise Newton, Ross Calley Anderson, Arieh Anthony Katz, et al.
Frontiers in Immunology|September 6, 2021
Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?Hillard M Lazarus, Carolyn E Ragsdale, Robert Peter Gale, et al.
The Journal of Trauma|February 13, 2004
Bone debris: dead matter or vital osteoblastsFlorian Hoegel, Christof A Mueller, Robert Peter, et al.
Nature Reviews. Disease Primers|November 17, 2022
Myelodysplastic syndromesHuan Li, Fang Hu, Robert Peter Gale, et al.
Bone Marrow Transplantation|August 20, 2021
A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncationZhen-Huan Hu, Hai-Lin Wang, Robert Peter Gale, et al.
Pageof 51

Showing results (91-100 of 505) with videos related to

Sort By:
Pageof 51
Acta Haematologica|September 17, 2015
Is Having Clonal Cytogenetic Abnormalities the Same as Having LeukaemiaMirko Farina, Giuseppe Rossi, Daniella Bellotti, et al.
Journal of Cancer Research and Clinical Oncology|April 18, 2016
Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemiaQian Jiang, Zheng-Chen Liu, Song-Xin Zhang, et al.
Acta Haematologica|July 6, 2026
Progression-free survival effect sizes in randomized controlled trials of targeted cancer therapies with positive outcomesWei Zhang, Wen Yan, Mengyun Chen, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 17, 2018
Tracking Kinematic and Kinetic Measures of Sit to Stand using an Instrumented Spine OrthosisRobert Peter Matthew, Sarah Seko, Jeannie Bailey, et al.
Journal of Sports Sciences|December 18, 2014
Lifesource XL-18 pedometer for measuring steps under controlled and free-living conditionsSam Liu, Dina Brooks, Scott Thomas, et al.
Endocrinology|August 18, 2016
Loss-of-Function Mutations in the Human Luteinizing Hormone Receptor Predominantly Cause Intracellular RetentionClaire Louise Newton, Ross Calley Anderson, Arieh Anthony Katz, et al.
Frontiers in Immunology|September 6, 2021
Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?Hillard M Lazarus, Carolyn E Ragsdale, Robert Peter Gale, et al.
The Journal of Trauma|February 13, 2004
Bone debris: dead matter or vital osteoblastsFlorian Hoegel, Christof A Mueller, Robert Peter, et al.
Nature Reviews. Disease Primers|November 17, 2022
Myelodysplastic syndromesHuan Li, Fang Hu, Robert Peter Gale, et al.
Bone Marrow Transplantation|August 20, 2021
A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncationZhen-Huan Hu, Hai-Lin Wang, Robert Peter Gale, et al.
Pageof 51